WOCKPHARMA2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2019-10-012019-12-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2019-10-012019-12-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2019-04-01 2020-03-31 2020-01-14 INR Crores Third quarter Single segment Pharmaceuticals 2019-10-01 2019-12-31 Unaudited Standalone 3287400000.00 197700000.00 3485100000.00 659100000.00 346700000.00 184100000.00 1062500000.00 515500000.00 438400000.00 1147400000.00 4353700000.00 -868600000.00 0.00 -868600000.00 36900000.00 -207100000.00 -170200000.00 0.00 -698400000.00 0.00 0.00 0.00 0.00 -698400000.00 -3500000.00 -701900000.00 0.00 0.00 553700000.00 5 -6.31 -6.31 0.00 0.00 -6.31 -6.31 1.The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 27, 2020. The results have been subjected to limited review by the Statutory Auditors of the Company. n n2.During the quarter, the Company has allotted Nil Year-to- date 48,800 Equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options. n n3.The Company has adopted Ind AS 116 – Leases beginning April 01, 2019 using the modified retrospective approach. The standard has been applied to all the lease contracts existing as on April 01, 2019. Accordingly, the Company has not restated comparative information and recognised a lease liability at present value of the lease payments discounted at the relevant incremental borrowing rate. The right-of-use asset has been measured at the same value as that of the lease liability subject to the adjustments for prepayments and accruals. For leases classified as finance lease, the carrying value of the lease asset and lease liability as at April 01, 2019, has been carried forward without change under the new standard. Consequent to the new standard, the Company has reported Right-of-Use assets amounting Rs. 644.25 crore, including reclassification of Lease hold land and Lease liability amounting to Rs. 519.75 crore as on April 01, 2019. n n4.The Company is exclusively into Pharmaceutical business Segment. n n5.Previous period or year figures have been recast or re-grouped to conform to the current period's presentation. Single segment 2019-04-01 2019-12-31 Unaudited Standalone 11052300000.00 303900000.00 11356200000.00 2069600000.00 1154800000.00 312800000.00 3502600000.00 1620800000.00 1302400000.00 3578800000.00 13541800000.00 -2185600000.00 0.00 -2185600000.00 36900000.00 -695500000.00 -658600000.00 0.00 -1527000000.00 0.00 0.00 0.00 0.00 -1527000000.00 -9100000.00 -1536100000.00 0.00 0.00 553700000.00 5 -13.79 -13.79 0.00 0.00 -13.79 -13.79 Exchange Fluctuation loss/ (gain),net -36000000.00 Other Expenses 1183400000.00 Exchange Fluctuation loss/ (gain),net -119800000.00 Other Expenses 3698600000.00